EC's orphan drug proposal

OXFORD - Europe took a step closer to having its own orphan drug legislation. After seven drafts and years of delay, the European Commission last week unveiled its proposal for a European orphan medicinal products regulation.

European pharmaceutical and biotech executives gave the proposal a qualified welcome.

Commission officials are proposing incentives to support companies developing compounds to treat diseases that affect fewer than 1 in 2000 European citizens or are life threatening or seriously debilitating communicable diseases for which products would not be developed without incentives to provide sufficient returns.

Orphan drug status will

Read the full 925 word article

How to gain access

Continue reading with a
two-week free trial.